167 related articles for article (PubMed ID: 32557577)
21. Phase II study of gefitinib in patients with advanced salivary gland cancers.
Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
[TBL] [Abstract][Full Text] [Related]
22. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.
Fushimi C; Tada Y; Takahashi H; Nagao T; Ojiri H; Masubuchi T; Matsuki T; Miura K; Kawakita D; Hirai H; Hoshino E; Kamata S; Saotome T
Ann Oncol; 2018 Apr; 29(4):979-984. PubMed ID: 29211833
[TBL] [Abstract][Full Text] [Related]
23. A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer.
Kim HR; Lee SJ; Park S; Jung HA; Lee SH; Jeong HS; Chung MK; Ahn MJ
Cancer Res Treat; 2022 Jul; 54(3):719-727. PubMed ID: 34727492
[TBL] [Abstract][Full Text] [Related]
24. Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
Jiang D; Dumur CI; Massey HD; Ramakrishnan V; Subler MA; Windle JJ
PLoS One; 2015; 10(2):e0118029. PubMed ID: 25695772
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Significance of HRAS Mutations in Epithelial-Myoepithelial Carcinomas Exhibiting a Broad Histopathologic Spectrum.
Urano M; Nakaguro M; Yamamoto Y; Hirai H; Tanigawa M; Saigusa N; Shimizu A; Tsukahara K; Tada Y; Sakurai K; Isomura M; Okumura Y; Yamaguchi H; Matsubayashi J; Nagao T
Am J Surg Pathol; 2019 Jul; 43(7):984-994. PubMed ID: 30994537
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.
Yam C; Murthy RK; Valero V; Szklaruk J; Shroff GS; Stalzer CJ; Buzdar AU; Murray JL; Yang W; Hortobagyi GN; Moulder SL; Arun B
Invest New Drugs; 2018 Apr; 36(2):299-306. PubMed ID: 29374384
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel and carboplatin for recurrent salivary gland malignancies.
Airoldi M; Fornari G; Pedani F; Marchionatti S; Gabriele P; Succo G; Bumma C
Anticancer Res; 2000; 20(5C):3781-3. PubMed ID: 11268454
[TBL] [Abstract][Full Text] [Related]
28. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.
Locati LD; Cavalieri S; Bergamini C; Resteghini C; Alfieri S; Calareso G; Bossi P; Perrone F; Tamborini E; Quattrone P; Granata R; Galbiati D; Platini F; Orlandi E; Mariani L; Licitra L
Head Neck; 2019 Oct; 41(10):3670-3676. PubMed ID: 31355973
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies.
Rodriguez CP; Martins RG; Baik C; Chow LQ; Santana-Davila R; Goulart BH; Lee S; Eaton KD
Head Neck; 2018 Mar; 40(3):584-589. PubMed ID: 29283469
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.
Ross JS; Gay LM; Wang K; Vergilio JA; Suh J; Ramkissoon S; Somerset H; Johnson JM; Russell J; Ali S; Schrock AB; Fabrizio D; Frampton G; Miller V; Stephens PJ; Elvin JA; Bowles DW
Ann Oncol; 2017 Oct; 28(10):2539-2546. PubMed ID: 28961851
[TBL] [Abstract][Full Text] [Related]
32. Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.
Rieke DT; Schröder S; Schafhausen P; Blanc E; Zuljan E; von der Emde B; Beule D; Keller U; Keilholz U; Klinghammer K
Front Oncol; 2023; 13():1107134. PubMed ID: 37427101
[TBL] [Abstract][Full Text] [Related]
33. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
34. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.
Hanna GJ; Bae JE; Lorch JH; Haddad RI; Jo VY; Schoenfeld JD; Margalit DN; Tishler RB; Goguen LA; Annino DJ; Chau NG
Oncologist; 2020 Jul; 25(7):598-608. PubMed ID: 32310325
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.
Rolland D; Ribrag V; Haioun C; Ghesquieres H; Jardin F; Bouabdallah R; Franchi P; Briere J; De Kerviler E; Chassagne-Clement C; Raponi M; Houlgatte R; Jais JP; Thieblemont C
Cancer Chemother Pharmacol; 2010 Mar; 65(4):781-90. PubMed ID: 19960345
[TBL] [Abstract][Full Text] [Related]
36. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Lebowitz PF; Eng-Wong J; Widemann BC; Balis FM; Jayaprakash N; Chow C; Clark G; Gantz SB; Venzon D; Zujewski J
Clin Cancer Res; 2005 Feb; 11(3):1247-52. PubMed ID: 15709195
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
Villalona-Calero MA; Lam E; Otterson GA; Zhao W; Timmons M; Subramaniam D; Hade EM; Gill GM; Coffey M; Selvaggi G; Bertino E; Chao B; Knopp MV
Cancer; 2016 Mar; 122(6):875-83. PubMed ID: 26709987
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Kuhn J; Robins HI; Abrey L; Wen P; Fink K; Lieberman FS; Mehta M; Chang S; Yung A; DeAngelis L; Schiff D; Junck L; Groves M; Paquette S; Wright J; Lamborn K; Sebti SM; Prados M
J Clin Oncol; 2005 Sep; 23(27):6647-56. PubMed ID: 16170172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
